The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for ...

Eli Lilly LLY-1.44%decrease; red down pointing triangle agreed to acquire Verve Therapeutics VERV 1.79%increase; green up pointing triangle for approximately $1 billion up front, adding a ...